The Motley Fool··Jonathan PoncianoBiotech Fund Bets on Vir's Pipeline as Stock Soars 99% on Clinical Catalysts
Superstring Capital deploys $5.82M into Vir Biotechnology amid 99% stock rally, betting on Phase 3 HDV and oncology catalysts expected in late 2026-2027.
VIRSMMTPhase 3 trialsbalance sheet strength